Latest Breaking News On - Early multiple system atrophy - Page 1 : comparemela.com

MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022. Multiple System Atrophy (MSA) is a progressive neurodegenerative disease that presents with motor and prominent autonomic symptoms. Major sources of disability in MSA result from motor symptoms characteristic of Parkinson's disease and impaired ability to maintain normal blood pressure, bowel function and bladder control. Problems with urination are a common symptom experienced in MSA and can occur at any time during the disease process. The poster, entitled, Urinary Symptom Profi

United statesSan franciscoDaniel claassenDavid stamlerVanderbilt university medical centerNational institute of healthAmerican autonomic societyEuropean commissionAlterity therapeuticsMultiple system atrophySystem atrophyUrinary symptom profileEarly multiple system atrophyChief executive officerAssociate professorNeurological disorders